gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Cytochrome P450, family 2, subfamily C, polypeptide 19

CYP2C19, cytochrome P450 2C19
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CYP3A4, CYP2C9, Cyp, CYP2D6, CYP1A1
Papers on CYP2C19
Assessment of platelet-derived thrombogenicity by the total thrombus-formation analysis system in coronary artery disease patients on antiplatelet therapy.
Ogawa et al., Kumamoto, Japan. In J Thromb Haemost, Feb 2016
In the aspirin/clopidogrel group, the PL24 -AUC10 was higher in poor metabolizers (PM) with cytochrome P-450 2C19(CYP2C19) polymorphism (152±112, 95% CI, 103.4-200.6)
Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy.
Kang et al., Xianyang, China. In Mol Med Report, Feb 2016
UNASSIGNED: Cytochrome P450 2C19 (CYP2C19) is a highly polymorphic gene, it codes for a protein responsible for the metabolism of multiple clinically important therapeutic agents.
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.
Boddy et al., Newcastle upon Tyne, United Kingdom. In Eur J Cancer, Feb 2016
Polymorphisms in genes including CYP2B6 and CYP2C19 were analysed.
Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method.
Okuyan et al., Houston, United States. In Expert Opin Drug Saf, Feb 2016
clopidogrel) could be justified in patients without strong affinity to cytochrome CYP2C19 and with high risk of bleeding (e.g.
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
Tayek et al., Los Angeles, United States. In Drug Metab Dispos, Jan 2016
Voriconazole is metabolized by both CYP2C19 and CYP3A4 isoenzymes.
Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Thuillez et al., Rouen, France. In Int J Antimicrob Agents, Jan 2016
This study aimed to assess (i) the impact of CYP2C19 genotype on VCZ exposure and (ii) the doses required to achieve the therapeutic range in adult patients with invasive fungal infections (IFIs).
Cannabinoids and Cytochrome P450 Interactions.
Juřica et al., Brno, Czech Republic. In Curr Drug Metab, Jan 2016
The enzymes CYP2C9, CYP2C19, and CYP3A4 catalyze most of their hydroxylations.
Pharmacogenetics of healthy volunteers in Puerto Rico.
Duconge et al., In Drug Metabol Personal Ther, Jan 2016
In addition, polymorphisms in genes that encode for members of the CYP450 family (CYP2C9, CYP2C19, and CYP2D6) are also available due to their relevance in the metabolism of drugs.
Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.
LLerena et al., Badajoz, Spain. In Pharmacogenomics J, Nov 2015
UNASSIGNED: The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and CYP2C19 metabolic phenotypes ('predicted' from genotypes and 'measured' with a probe drug) among healthy volunteers from different ethnic groups and geographic regions, as well as the relationship between the 'predicted' and 'measured' CYP2C19 metabolic phenotypes.
Effect of acute paraquat poisoning on CYP450 isoforms activity in rats by cocktail method.
Ma et al., Lishui, China. In Int J Clin Exp Med, 2014
The influence of acute paraquat poisoning on the activities of CYP450 isoforms CYP2B6, CYP1A2, CYP2C9, CYP2D6, CYP3A4 and CYP2C19 were evaluated by cocktail method, they were responded by the changes of pharmacokinetic parameters of bupropion, phenacetin, tolbutamide, metoprolol, midazolam and omeprazole.
Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming.
Deng et al., Beijing, China. In Cell Stem Cell, 2014
Importantly, the metabolic activities of CYP3A4, CYP1A2, CYP2B6, CYP2C9, and CYP2C19 are comparable between hiHeps and freshly isolated primary human hepatocytes.
Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
Cavallari et al., Gainesville, United States. In Pharmacol Rev, 2013
The body of literature that has led to the clinical implementation of CYP2C19 genotyping for clopidogrel, VKORC1, CYP2C9; and CYP4F2 for warfarin; and SLCO1B1 for statins is comprehensively described.
CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers.
Wang et al., Nanjing, China. In Pharmazie, 2012
The genetic polymorphism of CYP2C19 681G > A does not cause significant alterations in the pharmacokinetics of clopidogrel
[Prevalence of CYP2C19 polymorphisms involved in clopidogrel metabolism in Fujian Han population].
Lin et al., Fuzhou, China. In Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2012
The frequencies of CYP2C19*2, *3 and *17 were 32.4%, 5.8% and 0.4%, respectively.
[Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes].
Xu et al., Tianjin, China. In Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2012
Compared with homozygotes or heterozygotes for the wild-type CYP2C19*2, patients with CYP2C19*2 AA genotype had significantly higher PA on 7 and 21 days post PCI (P<0.05).
Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
GIFT Investigators et al., Los Angeles, United States. In J Am Coll Cardiol, 2012
In patients with high OTR identified by platelet function testing, the CYP2C19 genotype provides limited incremental information regarding the risk of persistently high reactivity with clopidogrel 150-mg maintenance dosing.
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
Casas et al., London, United Kingdom. In Jama, 2012
CONTEXT: The US Food and Drug Administration recently recommended that CYP2C19 genotyping be considered prior to prescribing clopidogrel, but the American Heart Association and American College of Cardiologists have argued evidence is insufficient to support CYP2C19 genotype testing.
[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
Galiavi et al., In Kardiologiia, 2011
Was not found difference in the prevalence of CYP2C19 gene polymorphism in different forms of myocardial infarction and there are no influence on prognosis if the patient follow medical recommendations, including the regular use of clopidogrel.
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
Sabatine et al., Boston, United States. In Jama, 2011
CONTEXT: Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.
Collet et al., Paris, France. In Jama, 2011
This case-control study identified 3 genes (CYP2C19, ABCB1, and ITGB3) and 2 clopidogrel-related factors (loading dose and proton pump inhibitors) that were independently associated with early stent thrombosis
share on facebooktweetadd +1mail to friends